ID   SCRB1_HUMAN             Reviewed;         552 AA.
AC   Q8WTV0; F8W8N0; Q14016; Q52LZ5; Q6KFX4;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   10-MAY-2017, entry version 156.
DE   RecName: Full=Scavenger receptor class B member 1;
DE            Short=SRB1;
DE   AltName: Full=CD36 and LIMPII analogous 1;
DE            Short=CLA-1;
DE   AltName: Full=CD36 antigen-like 1;
DE   AltName: Full=Collagen type I receptor, thrombospondin receptor-like 1;
DE   AltName: Full=SR-BI;
DE   AltName: CD_antigen=CD36;
GN   Name=SCARB1; Synonyms=CD36L1, CLA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Promyelocyte;
RX   PubMed=7689561;
RA   Calvo D., Vega M.;
RT   "Identification, primary structure and distribution of CLA-1, a novel
RT   member of the CD36/LIMPII gene family.";
RL   J. Biol. Chem. 268:18929-18935(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RA   Hirano K., Yamashita S., Matsuzawa Y.;
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Liver, Prostate, and Rhabdomyosarcoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION.
RX   PubMed=12356718; DOI=10.1093/emboj/cdf529;
RA   Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S.,
RA   Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A.;
RT   "The human scavenger receptor class B type I is a novel candidate
RT   receptor for the hepatitis C virus.";
RL   EMBO J. 21:5017-5025(2002).
RN   [7]
RP   FUNCTION, AND GLYCOSYLATION.
RX   PubMed=12016218; DOI=10.1074/jbc.M202879200;
RA   Kawasaki Y., Nakagawa A., Nagaosa K., Shiratsuchi A., Nakanishi Y.;
RT   "Phosphatidylserine binding of class B scavenger receptor type I, a
RT   phagocytosis receptor of testicular Sertoli cells.";
RL   J. Biol. Chem. 277:27559-27566(2002).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH HCV E1/E2 ENVELOPE HETERODIMER.
RX   PubMed=12913001; DOI=10.1074/jbc.M305289200;
RA   Bartosch B., Vitelli A., Granier C., Goujon C., Dubuisson J.,
RA   Pascale S., Scarselli E., Cortese R., Nicosia A., Cosset F.-L.;
RT   "Cell entry of hepatitis C virus requires a set of co-receptors that
RT   include the CD81 tetraspanin and the SR-B1 scavenger receptor.";
RL   J. Biol. Chem. 278:41624-41630(2003).
RN   [9]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=16020694; DOI=10.1126/science.1116006;
RA   Philips J.A., Rubin E.J., Perrimon N.;
RT   "Drosophila RNAi screen reveals CD36 family member required for
RT   mycobacterial infection.";
RL   Science 309:1251-1253(2005).
RN   [10]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HEPATITIS C VIRUS
RP   E1 AND E2 GLYCOPROTEINS.
RX   PubMed=18000990; DOI=10.1002/hep.21994;
RA   Zeisel M.B., Koutsoudakis G., Schnober E.K., Haberstroh A., Blum H.E.,
RA   Cosset F.L., Wakita T., Jaeck D., Doffoel M., Royer C., Soulier E.,
RA   Schvoerer E., Schuster C., Stoll-Keller F., Bartenschlager R.,
RA   Pietschmann T., Barth H., Baumert T.F.;
RT   "Scavenger receptor class B type I is a key host factor for hepatitis
RT   C virus infection required for an entry step closely linked to CD81.";
RL   Hepatology 46:1722-1731(2007).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-102 AND ASN-330.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [12]
RP   INVOLVEMENT IN HDLCQ16.
RX   PubMed=20686565; DOI=10.1038/nature09270;
RA   Teslovich T.M., Musunuru K., Smith A.V., Edmondson A.C.,
RA   Stylianou I.M., Koseki M., Pirruccello J.P., Ripatti S., Chasman D.I.,
RA   Willer C.J., Johansen C.T., Fouchier S.W., Isaacs A., Peloso G.M.,
RA   Barbalic M., Ricketts S.L., Bis J.C., Aulchenko Y.S., Thorleifsson G.,
RA   Feitosa M.F., Chambers J., Orho-Melander M., Melander O., Johnson T.,
RA   Li X., Guo X., Li M., Shin Cho Y., Jin Go M., Jin Kim Y., Lee J.Y.,
RA   Park T., Kim K., Sim X., Twee-Hee Ong R., Croteau-Chonka D.C.,
RA   Lange L.A., Smith J.D., Song K., Hua Zhao J., Yuan X., Luan J.,
RA   Lamina C., Ziegler A., Zhang W., Zee R.Y., Wright A.F., Witteman J.C.,
RA   Wilson J.F., Willemsen G., Wichmann H.E., Whitfield J.B.,
RA   Waterworth D.M., Wareham N.J., Waeber G., Vollenweider P.,
RA   Voight B.F., Vitart V., Uitterlinden A.G., Uda M., Tuomilehto J.,
RA   Thompson J.R., Tanaka T., Surakka I., Stringham H.M., Spector T.D.,
RA   Soranzo N., Smit J.H., Sinisalo J., Silander K., Sijbrands E.J.,
RA   Scuteri A., Scott J., Schlessinger D., Sanna S., Salomaa V.,
RA   Saharinen J., Sabatti C., Ruokonen A., Rudan I., Rose L.M.,
RA   Roberts R., Rieder M., Psaty B.M., Pramstaller P.P., Pichler I.,
RA   Perola M., Penninx B.W., Pedersen N.L., Pattaro C., Parker A.N.,
RA   Pare G., Oostra B.A., O'Donnell C.J., Nieminen M.S., Nickerson D.A.,
RA   Montgomery G.W., Meitinger T., McPherson R., McCarthy M.I.,
RA   McArdle W., Masson D., Martin N.G., Marroni F., Mangino M.,
RA   Magnusson P.K., Lucas G., Luben R., Loos R.J., Lokki M.L., Lettre G.,
RA   Langenberg C., Launer L.J., Lakatta E.G., Laaksonen R., Kyvik K.O.,
RA   Kronenberg F., Konig I.R., Khaw K.T., Kaprio J., Kaplan L.M.,
RA   Johansson A., Jarvelin M.R., Janssens A.C., Ingelsson E., Igl W.,
RA   Kees Hovingh G., Hottenga J.J., Hofman A., Hicks A.A.,
RA   Hengstenberg C., Heid I.M., Hayward C., Havulinna A.S., Hastie N.D.,
RA   Harris T.B., Haritunians T., Hall A.S., Gyllensten U., Guiducci C.,
RA   Groop L.C., Gonzalez E., Gieger C., Freimer N.B., Ferrucci L.,
RA   Erdmann J., Elliott P., Ejebe K.G., Doring A., Dominiczak A.F.,
RA   Demissie S., Deloukas P., de Geus E.J., de Faire U., Crawford G.,
RA   Collins F.S., Chen Y.D., Caulfield M.J., Campbell H., Burtt N.P.,
RA   Bonnycastle L.L., Boomsma D.I., Boekholdt S.M., Bergman R.N.,
RA   Barroso I., Bandinelli S., Ballantyne C.M., Assimes T.L.,
RA   Quertermous T., Altshuler D., Seielstad M., Wong T.Y., Tai E.S.,
RA   Feranil A.B., Kuzawa C.W., Adair L.S., Taylor H.A. Jr., Borecki I.B.,
RA   Gabriel S.B., Wilson J.G., Holm H., Thorsteinsdottir U., Gudnason V.,
RA   Krauss R.M., Mohlke K.L., Ordovas J.M., Munroe P.B., Kooner J.S.,
RA   Tall A.R., Hegele R.A., Kastelein J.J., Schadt E.E., Rotter J.I.,
RA   Boerwinkle E., Strachan D.P., Mooser V., Stefansson K., Reilly M.P.,
RA   Samani N.J., Schunkert H., Cupples L.A., Sandhu M.S., Ridker P.M.,
RA   Rader D.J., van Duijn C.M., Peltonen L., Abecasis G.R., Boehnke M.,
RA   Kathiresan S.;
RT   "Biological, clinical and population relevance of 95 loci for blood
RT   lipids.";
RL   Nature 466:707-713(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-493 (ISOFORM 1),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-393 (ISOFORM 2),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-458 (ISOFORM 4), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN HDLCQ16, VARIANT
RP   LEU-376, AND CHARACTERIZATION OF VARIANT LEU-376.
RX   PubMed=26965621; DOI=10.1126/science.aad3517;
RG   CHD Exome+ Consortium;
RG   CARDIoGRAM Exome Consortium;
RG   Global Lipids Genetics Consortium;
RA   Zanoni P., Khetarpal S.A., Larach D.B., Hancock-Cerutti W.F.,
RA   Millar J.S., Cuchel M., DerOhannessian S., Kontush A., Surendran P.,
RA   Saleheen D., Trompet S., Jukema J.W., De Craen A., Deloukas P.,
RA   Sattar N., Ford I., Packard C., Majumder A., Alam D.S.,
RA   Di Angelantonio E., Abecasis G., Chowdhury R., Erdmann J.,
RA   Nordestgaard B.G., Nielsen S.F., Tybjaerg-Hansen A., Schmidt R.F.,
RA   Kuulasmaa K., Liu D.J., Perola M., Blankenberg S., Salomaa V.,
RA   Maennistoe S., Amouyel P., Arveiler D., Ferrieres J.,
RA   Mueller-Nurasyid M., Ferrario M., Kee F., Willer C.J., Samani N.,
RA   Schunkert H., Butterworth A.S., Howson J.M., Peloso G.M.,
RA   Stitziel N.O., Danesh J., Kathiresan S., Rader D.J.;
RT   "Rare variant in scavenger receptor BI raises HDL cholesterol and
RT   increases risk of coronary heart disease.";
RL   Science 351:1166-1171(2016).
RN   [16]
RP   FUNCTION, AND VARIANT SER-2.
RX   PubMed=12519372; DOI=10.1034/j.1399-0004.2003.630108.x;
RA   Tai E.S., Adiconis X., Ordovas J.M., Carmena-Ramon R., Real J.,
RA   Corella D., Ascaso J., Carmena R.;
RT   "Polymorphisms at the SRBI locus are associated with lipoprotein
RT   levels in subjects with heterozygous familial hypercholesterolemia.";
RL   Clin. Genet. 63:53-58(2003).
RN   [17]
RP   VARIANTS SER-2; ILE-135 AND SER-167.
RX   PubMed=12966036; DOI=10.1093/hmg/ddg314;
RA   Morabia A., Cayanis E., Costanza M.C., Ross B.M., Flaherty M.S.,
RA   Alvin G.B., Das K., Gilliam T.C.;
RT   "Association of extreme blood lipid profile phenotypic variation with
RT   11 reverse cholesterol transport genes and 10 non-genetic
RT   cardiovascular disease risk factors.";
RL   Hum. Mol. Genet. 12:2733-2743(2003).
RN   [18]
RP   FUNCTION, VARIANT SER-297, AND INVOLVEMENT IN HDLCQ16.
RX   PubMed=21226579; DOI=10.1056/NEJMoa0907687;
RA   Vergeer M., Korporaal S.J., Franssen R., Meurs I., Out R.,
RA   Hovingh G.K., Hoekstra M., Sierts J.A., Dallinga-Thie G.M.,
RA   Motazacker M.M., Holleboom A.G., Van Berkel T.J., Kastelein J.J.,
RA   Van Eck M., Kuivenhoven J.A.;
RT   "Genetic variant of the scavenger receptor BI in humans.";
RL   N. Engl. J. Med. 364:136-145(2011).
CC   -!- FUNCTION: Receptor for different ligands such as phospholipids,
CC       cholesterol ester, lipoproteins, phosphatidylserine and apoptotic
CC       cells (PubMed:12016218, PubMed:12519372, PubMed:21226579).
CC       Facilitates the flux of free and esterified cholesterol between
CC       the cell surface and extracellular donors and acceptors, such as
CC       high density lipoproteins (HDL) and to a lesser extent, apoB-
CC       containing lipoproteins and modified lipoproteins. Necessary for
CC       selective HDL-cholesterol uptake (PubMed:26965621). Probably
CC       involved in the phagocytosis of apoptotic cells, via its
CC       phosphatidylserine binding activity (PubMed:12016218).
CC       {ECO:0000269|PubMed:12016218, ECO:0000269|PubMed:12519372,
CC       ECO:0000269|PubMed:16020694, ECO:0000269|PubMed:21226579,
CC       ECO:0000269|PubMed:26965621}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C
CC       virus in hepatocytes and appears to facilitate its cell entry
CC       (PubMed:12356718, PubMed:12913001, PubMed:18000990). Binding
CC       between SCARB1 and the hepatitis C virus glycoprotein E2 is
CC       independent of the genotype of the viral isolate
CC       (PubMed:12356718). Mediates uptake of M.fortuitum, E.coli and
CC       S.aureus (PubMed:16020694). {ECO:0000269|PubMed:12356718,
CC       ECO:0000269|PubMed:16020694, ECO:0000269|PubMed:18000990}.
CC   -!- SUBUNIT: The C-terminal region binds to PDZK1.
CC       {ECO:0000250|UniProtKB:P97943}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with hepatitis C virus
CC       E1:E2 glycoproteins. {ECO:0000269|PubMed:18000990}.
CC   -!- INTERACTION:
CC       P27958:- (xeno); NbExp=2; IntAct=EBI-78657, EBI-6904269;
CC       P60411:KRTAP10-9; NbExp=3; IntAct=EBI-78657, EBI-10172052;
CC       P26371:KRTAP5-9; NbExp=3; IntAct=EBI-78657, EBI-3958099;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26965621};
CC       Multi-pass membrane protein. Membrane, caveola; Multi-pass
CC       membrane protein. Note=Predominantly localized to cholesterol and
CC       sphingomyelin-enriched domains within the plasma membrane, called
CC       caveolae.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=3;
CC         IsoId=Q8WTV0-1; Sequence=Displayed;
CC         Note=May be due to a competing donor splice site. No
CC         experimental confirmation available.;
CC       Name=1; Synonyms=SR-BI;
CC         IsoId=Q8WTV0-2; Sequence=VSP_008554;
CC         Note=Contains a phosphoserine at position 493.
CC         {ECO:0000244|PubMed:24275569};
CC       Name=2; Synonyms=SR-BII;
CC         IsoId=Q8WTV0-3; Sequence=VSP_008553, VSP_008554;
CC         Note=Contains a phosphoserine at position 393.
CC         {ECO:0000244|PubMed:24275569};
CC       Name=4; Synonyms=SR-BIII;
CC         IsoId=Q8WTV0-4; Sequence=VSP_011037, VSP_008554;
CC         Note=Contains a phosphoserine at position 458.
CC         {ECO:0000244|PubMed:24275569};
CC       Name=5;
CC         IsoId=Q8WTV0-5; Sequence=VSP_054083;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on EST data.;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:12016218,
CC       ECO:0000269|PubMed:19159218}.
CC   -!- PTM: The six cysteines of the extracellular domain are all
CC       involved in intramolecular disulfide bonds.
CC       {ECO:0000250|UniProtKB:Q61009}.
CC   -!- POLYMORPHISM: Genetic variations in SCARB1 define the high density
CC       lipoprotein cholesterol level quantitative trait locus 6 (HDLCQ16)
CC       [MIM:610762]. {ECO:0000269|PubMed:20686565,
CC       ECO:0000269|PubMed:21226579, ECO:0000269|PubMed:26965621}.
CC   -!- SIMILARITY: Belongs to the CD36 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z22555; CAA80277.1; -; mRNA.
DR   EMBL; AF515445; AAQ08185.1; -; mRNA.
DR   EMBL; AC073593; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC126309; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471054; EAW98459.1; -; Genomic_DNA.
DR   EMBL; BC022087; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC080647; AAH80647.1; -; mRNA.
DR   EMBL; BC093732; AAH93732.1; -; mRNA.
DR   EMBL; BC112037; AAI12038.1; -; mRNA.
DR   CCDS; CCDS45008.1; -. [Q8WTV0-5]
DR   CCDS; CCDS9259.1; -. [Q8WTV0-2]
DR   PIR; S36656; A48528.
DR   RefSeq; NP_001076428.1; NM_001082959.1. [Q8WTV0-5]
DR   RefSeq; NP_005496.4; NM_005505.4. [Q8WTV0-2]
DR   UniGene; Hs.731377; -.
DR   ProteinModelPortal; Q8WTV0; -.
DR   SMR; Q8WTV0; -.
DR   BioGrid; 107387; 26.
DR   IntAct; Q8WTV0; 10.
DR   MINT; MINT-5001419; -.
DR   STRING; 9606.ENSP00000261693; -.
DR   BindingDB; Q8WTV0; -.
DR   ChEMBL; CHEMBL1914272; -.
DR   DrugBank; DB00144; Phosphatidyl serine.
DR   SwissLipids; SLP:000001519; -.
DR   TCDB; 9.B.39.1.3; the long chain fatty acid translocase (lcfat) family.
DR   iPTMnet; Q8WTV0; -.
DR   PhosphoSitePlus; Q8WTV0; -.
DR   SwissPalm; Q8WTV0; -.
DR   BioMuta; SCARB1; -.
DR   DMDM; 37999904; -.
DR   EPD; Q8WTV0; -.
DR   MaxQB; Q8WTV0; -.
DR   PaxDb; Q8WTV0; -.
DR   PeptideAtlas; Q8WTV0; -.
DR   PRIDE; Q8WTV0; -.
DR   DNASU; 949; -.
DR   Ensembl; ENST00000261693; ENSP00000261693; ENSG00000073060. [Q8WTV0-2]
DR   Ensembl; ENST00000339570; ENSP00000343795; ENSG00000073060. [Q8WTV0-5]
DR   Ensembl; ENST00000415380; ENSP00000414979; ENSG00000073060. [Q8WTV0-1]
DR   GeneID; 949; -.
DR   KEGG; hsa:949; -.
DR   UCSC; uc001ugm.5; human. [Q8WTV0-1]
DR   CTD; 949; -.
DR   DisGeNET; 949; -.
DR   GeneCards; SCARB1; -.
DR   HGNC; HGNC:1664; SCARB1.
DR   HPA; CAB070124; -.
DR   HPA; HPA066285; -.
DR   MIM; 601040; gene.
DR   MIM; 610762; phenotype.
DR   neXtProt; NX_Q8WTV0; -.
DR   OpenTargets; ENSG00000073060; -.
DR   PharmGKB; PA97; -.
DR   eggNOG; KOG3776; Eukaryota.
DR   eggNOG; ENOG410XS17; LUCA.
DR   GeneTree; ENSGT00530000062927; -.
DR   HOVERGEN; HBG106577; -.
DR   InParanoid; Q8WTV0; -.
DR   KO; K13885; -.
DR   OMA; MWKEIPI; -.
DR   OrthoDB; EOG091G0CH9; -.
DR   PhylomeDB; Q8WTV0; -.
DR   TreeFam; TF317925; -.
DR   Reactome; R-HSA-194223; HDL-mediated lipid transport.
DR   Reactome; R-HSA-3000471; Scavenging by Class B Receptors.
DR   ChiTaRS; SCARB1; human.
DR   GeneWiki; SCARB1; -.
DR   GenomeRNAi; 949; -.
DR   PRO; PR:Q8WTV0; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000073060; -.
DR   CleanEx; HS_SCARB1; -.
DR   ExpressionAtlas; Q8WTV0; baseline and differential.
DR   Genevisible; Q8WTV0; HS.
DR   GO; GO:0005901; C:caveola; TAS:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; ISS:BHF-UCL.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:Ensembl.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0031528; C:microvillus membrane; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005545; F:1-phosphatidylinositol binding; TAS:BHF-UCL.
DR   GO; GO:0034186; F:apolipoprotein A-I binding; IPI:BHF-UCL.
DR   GO; GO:0034185; F:apolipoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0008035; F:high-density lipoprotein particle binding; IEA:Ensembl.
DR   GO; GO:0070506; F:high-density lipoprotein particle receptor activity; IDA:BHF-UCL.
DR   GO; GO:0001530; F:lipopolysaccharide binding; IDA:BHF-UCL.
DR   GO; GO:0001875; F:lipopolysaccharide receptor activity; IDA:BHF-UCL.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; IDA:BHF-UCL.
DR   GO; GO:0001786; F:phosphatidylserine binding; ISS:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0005215; F:transporter activity; TAS:ProtInc.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0044406; P:adhesion of symbiont to host; IMP:BHF-UCL.
DR   GO; GO:0006702; P:androgen biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043534; P:blood vessel endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0006707; P:cholesterol catabolic process; IEA:Ensembl.
DR   GO; GO:0033344; P:cholesterol efflux; IMP:AgBase.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISS:BHF-UCL.
DR   GO; GO:0070508; P:cholesterol import; IMP:UniProtKB.
DR   GO; GO:0032497; P:detection of lipopolysaccharide; IDA:BHF-UCL.
DR   GO; GO:0001935; P:endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; ISS:BHF-UCL.
DR   GO; GO:0050892; P:intestinal absorption; IEA:Ensembl.
DR   GO; GO:0015920; P:lipopolysaccharide transport; IDA:BHF-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0034383; P:low-density lipoprotein particle clearance; ISS:BHF-UCL.
DR   GO; GO:0015914; P:phospholipid transport; ISS:BHF-UCL.
DR   GO; GO:0010886; P:positive regulation of cholesterol storage; IDA:BHF-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; TAS:BHF-UCL.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:BHF-UCL.
DR   GO; GO:0010867; P:positive regulation of triglyceride biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0043654; P:recognition of apoptotic cell; IDA:BHF-UCL.
DR   GO; GO:0050764; P:regulation of phagocytosis; IC:BHF-UCL.
DR   GO; GO:0010899; P:regulation of phosphatidylcholine catabolic process; ISS:BHF-UCL.
DR   GO; GO:0043691; P:reverse cholesterol transport; IEP:BHF-UCL.
DR   GO; GO:0070328; P:triglyceride homeostasis; ISS:BHF-UCL.
DR   GO; GO:0035461; P:vitamin transmembrane transport; IMP:AgBase.
DR   GO; GO:0042060; P:wound healing; TAS:BHF-UCL.
DR   InterPro; IPR005428; CD36/SCARB1/SNMP1.
DR   InterPro; IPR002159; CD36_fam.
DR   PANTHER; PTHR11923; PTHR11923; 1.
DR   Pfam; PF01130; CD36; 1.
DR   PRINTS; PR01610; CD36ANTIGEN.
DR   PRINTS; PR01609; CD36FAMILY.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disulfide bond; Glycoprotein; Host cell receptor for virus entry;
KW   Host-virus interaction; Membrane; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN         1    552       Scavenger receptor class B member 1.
FT                                /FTId=PRO_0000144160.
FT   TOPO_DOM      1     11       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     12     32       Helical. {ECO:0000255}.
FT   TOPO_DOM     33    443       Extracellular. {ECO:0000255}.
FT   TRANSMEM    444    464       Helical. {ECO:0000255}.
FT   TOPO_DOM    465    552       Cytoplasmic. {ECO:0000255}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    108    108       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    173    173       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    212    212       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    227    227       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    255    255       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    310    310       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    330    330       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    383    383       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    251    384       {ECO:0000250}.
FT   VAR_SEQ       1     42       MGCSAKARWAAGALGVAGLLCAVLGAVMIVMVPSLIKQQVL
FT                                K -> MALQPSW (in isoform 4).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_011037.
FT   VAR_SEQ      43    142       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:7689561}.
FT                                /FTId=VSP_008553.
FT   VAR_SEQ     468    552       VGAGQRAARADSHSLACWGKGASDRTLWPTAAWSPPPAAVL
FT                                RLCRSGSGHCWGLRSTLASFACRVATTLPVLEGLGPSLGGG
FT                                TGS -> EKCYLFWSSSKKGSKDKEAIQAYSESLMTSAPKG
FT                                SVLQEAKL (in isoform 1, isoform 2 and
FT                                isoform 4). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7689561,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_008554.
FT   VAR_SEQ     468    552       VGAGQRAARADSHSLACWGKGASDRTLWPTAAWSPPPAAVL
FT                                RLCRSGSGHCWGLRSTLASFACRVATTLPVLEGLGPSLGGG
FT                                TGS -> GPEDTVSQPGLAAGPDRPPSPYTPLLPDSPSGQP
FT                                PSPTA (in isoform 5). {ECO:0000305}.
FT                                /FTId=VSP_054083.
FT   VARIANT       2      2       G -> S (associated with higher plasma
FT                                triglyceride concentration in subjects
FT                                with hypercholesterolemia;
FT                                dbSNP:rs4238001).
FT                                {ECO:0000269|PubMed:12519372,
FT                                ECO:0000269|PubMed:12966036}.
FT                                /FTId=VAR_017098.
FT   VARIANT     135    135       V -> I (in dbSNP:rs5891).
FT                                {ECO:0000269|PubMed:12966036}.
FT                                /FTId=VAR_017099.
FT   VARIANT     167    167       G -> S (in dbSNP:rs199588922).
FT                                {ECO:0000269|PubMed:12966036}.
FT                                /FTId=VAR_017100.
FT   VARIANT     229    229       S -> G (in dbSNP:rs10396213).
FT                                /FTId=VAR_019507.
FT   VARIANT     297    297       P -> S (mutation carriers have increased
FT                                HDL cholesterol levels and a reduction in
FT                                cholesterol efflux from macrophages;
FT                                dbSNP:rs387906791).
FT                                {ECO:0000269|PubMed:21226579}.
FT                                /FTId=VAR_064909.
FT   VARIANT     376    376       P -> L (rare variant; associated with
FT                                high HDL-cholesterol levels and increased
FT                                risk for coronary heart disease; results
FT                                in highly reduced cholesterol uptake from
FT                                HDL; markedly reduced localization at the
FT                                cell surface; dbSNP:rs74830677).
FT                                {ECO:0000269|PubMed:26965621}.
FT                                /FTId=VAR_076314.
FT   VARIANT     511    511       C -> R (in dbSNP:rs2293440).
FT                                /FTId=VAR_017101.
FT   CONFLICT     70     70       F -> L (in Ref. 2; AAQ08185).
FT                                {ECO:0000305}.
FT   CONFLICT     97     97       F -> S (in Ref. 1; CAA80277).
FT                                {ECO:0000305}.
SQ   SEQUENCE   552 AA;  60878 MW;  06B0BD771FEA284F CRC64;
     MGCSAKARWA AGALGVAGLL CAVLGAVMIV MVPSLIKQQV LKNVRIDPSS LSFNMWKEIP
     IPFYLSVYFF DVMNPSEILK GEKPQVRERG PYVYREFRHK SNITFNNNDT VSFLEYRTFQ
     FQPSKSHGSE SDYIVMPNIL VLGAAVMMEN KPMTLKLIMT LAFTTLGERA FMNRTVGEIM
     WGYKDPLVNL INKYFPGMFP FKDKFGLFAE LNNSDSGLFT VFTGVQNISR IHLVDKWNGL
     SKVDFWHSDQ CNMINGTSGQ MWPPFMTPES SLEFYSPEAC RSMKLMYKES GVFEGIPTYR
     FVAPKTLFAN GSIYPPNEGF CPCLESGIQN VSTCRFSAPL FLSHPHFLNA DPVLAEAVTG
     LHPNQEAHSL FLDIHPVTGI PMNCSVKLQL SLYMKSVAGI GQTGKIEPVV LPLLWFAESG
     AMEGETLHTF YTQLVLMPKV MHYAQYVLLA LGCVLLLVPV ICQIRSQVGA GQRAARADSH
     SLACWGKGAS DRTLWPTAAW SPPPAAVLRL CRSGSGHCWG LRSTLASFAC RVATTLPVLE
     GLGPSLGGGT GS
//
